tbuckley/cabot-search huggingface dataset:
Abstract 021: Retinol Binding Protein-4 and Fetuin-A Predict Incident Metabolic Syndrome and Metabolic Tracking Prospectively in Younger Adults: A Multimarker Adipokine Panel Approach from the Framingham Study
Authors: Rene Quiroz, Kerrie P Nelson, John F Keaney, Emelia J Benjamin, Lisa M Sullivan, Ramachandran S Vasan
Journal: Circulation (2012)

Introduction: Recent investigations have highlighted the central role of mediators produced by adipose tissue in the pathogenesis of metabolic dysregulation. We evaluated a multimarker panel of 6 adipokines (adiponectin, leptin, leptin receptor, fetuin-A, adipocyte-fatty acid binding proteins, retinol binding protein-4 [RBP4]) and related them prospectively to the incidence of metabolic syndrome (MetS) and change in metabolic traits on follow-up in a community-based sample of younger adults. We hypothesized that these adipokines would be associated with incidence of MetS and with longitudinal tracking of its components. Methods and Results: We evaluated the adipokine panel measured in 2208 Framingham third generation cohort participants (55% women; mean age 40 years). On follow-up (mean 6 years), 253 individuals developed new-onset MetS. After adjustment for standard clinical risk factors, the multimarker adipokine panel was associated with incident MetS (P = 0.002). Using a backward elimination process, both RBP4 and fetuin-A were significantly associated with development of MetS (multivariable-adjusted OR per 1-SD increment log marker, 1.23 [P= 0.01] and 1.17 [P= 0.03], respectively). Using the group with both the RBP4 and fetuin-A under the median serving as the referent, individuals with levels of both RBP4 and fetuin-A above the median experienced an increased risk for developing MetS (multivariable adjusted OR = 1.7 [95% CI, 1.10 - 2.65], P = 0.01). In multivariable adjusted logistic regression models, both RBP4 and fetuin-A were significantly associated with an increase in systolic BP (P =0.004 and P = 0.045, respectively) and increased fasting glucose. In addition, RBP4 was significantly associated with longitudinal increase in diastolic BP (P = 0.007). Conclusions: Our findings, based on prospective follow-up of a large community-based sample of younger adults, suggest higher levels of RBP4 and fetuin-A are associated with incident MetS and may constitute potential future therapeutic targets.
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Following Fludarabine Plus 2 Gy TBI or ATG Plus 8 Gy TLI: A Phase II Randomized Study from the Belgian Hematological Society
Authors: Yves Beguin, Pierre Zachee, Johan Maertens, Tessa Kerre, Aurelie Ory, Laurence Seidel, Carlos Graux, Philippe Lewalle, Michel Van Gelder, Koen Theunissen, Evelyne Willems, Marie-Paule Emonds, Ann De Becker, Frederic Baron
Journal: Blood (2014)
대간간학회지 제6차 춘계학술대회 초록집 : 포스터 발표 ; 간경변증 환자의 영양상태 개선에 있어서 경구용 분지 아미노산제 (LIVACT(R) 과립)의 유용성
Authors: 김명수 ( Kim Myeong Su ), 한광협 ( Han Gwang Hyeob ), 백용한 ( Baeg Yong Han ), 안상훈 ( An Sang Hun ), 윤석화 ( Yun Seog Hwa ), 전재윤 ( Jeon Jae Yun ), 문영명 ( Mun Yeong Myeong ), 이종호 ( Lee Jong Ho )
Journal: Clinical and Molecular Hepatology (2000)
Preoperative chemoradiotherapy for locally advanced resectable rectal cancer
Authors: M. Martinez, C. Del Rio, M. Navarro, L. Pareja, M. Martinez-Villacampa, E. Dotor, J Rodon, M Cambray
Journal: Journal of Clinical Oncology (2004)

3756 Background: The goal of preoperative treatment of invasive rectal cancer is to improve the overall survival and to decrease the local failure and the stage and to enhance sphincter preservation. The authors report the results of their institution. Methods: From 4/96 to 12/00 we have treated 119 patients (85 men, 34 women). Median age 62 years (20–77). All patients with resectable rectal cancer, stage: II: 24 pts, III: 89 pts, T3–4 Nx: 6. All of them have been treated with normofractionated radiotherapy (RT): total dose: 45 Gy, 1,8 Gy/day, 5 days (d) a week (w), 5 w, and concurrent chemotherapy (CH) with 5-FU 300mg/m2/d continuous infusion, 5d/w (79) or 7d/w (40). 6–8 w after they finished the CH-RT they underwent the radical surgery (RS) followed by 4 cycles of CH with 5-FU and LV (Mayo Clinic). Results: 118 pts finished the CH, and all the pts completed the RT. Acute toxicity: angor G3 (1), diarrhea G3 (2). 110 pts had RS, 8 pts palliative resection and 1 pt was not operated due to progression. 32/77 preserve the sphincter. 3 pts died after surgery (2,5%). The pathological overall response was 64,7 % (77 pts), 18 complete response (CR), 59 partial response (PR) in which 28 were microscopical residual disease. 37 stabilization (SD) and 5 progression. The recurrence rate was: 27% (4,5% local failure, 20% systemic and 2,7% local and systemic). With a median follow up of 34,23 m (0,23–82 m) 3 y overall survival (OS) was 78,76%. Pts with RS OS: 83,22%, and progression free survival (PFS) 70,39%. Conclusions: Our results are similar to the literature. Preoperative CH-RT is a well-tolerated treatment with high overall survival and a decrease in local failure. We have found that pts without response have a worse prognostic, it should be interesting to identify and include them in clinical trials. No significant financial relationships to disclose.
Allogeneic Hematopoietic Stem-Cell Transplantation After Nonmyeloablative Preparative Regimens: Impact of Pretransplantation and Posttransplantation Factors on Outcome
Authors: Mauricette Michallet, Karin Bilger, Frédéric Garban, Michel Attal, Anne Huyn, Didier Blaise, Noël Milpied, Philippe Moreau, Pierre Bordigoni, Mathieu Kuentz, Alain Sadoun, Jean-Yves Cahn, Gérard Socié, Xavier Thomas, Philippe Arnaud, Nicole Raus, Véronique Lhéritier, Arnaud Pigneux, Jean-Michel Boiron
Journal: Journal of Clinical Oncology (2001)

To analyze the impact of pre- and posttransplantation factors on the outcome of allogeneic transplantation after nonmyeloablative conditioning regimens.Ninety-two allogeneic transplantations after nonmyeloablative preparative regimens were reported to the Société Française de Greffe de Moelle Registry registry. Initial diagnoses were lymphoid diseases (n = 22), myeloma (n = 14), acute leukemia and myelodysplasia (n = 41), chronic myelogenous leukemia (n = 12), and solid tumors (n = 3). Forty-six patients had previously received a transplant, and 49 had progressive disease before transplantation. Three types of conditioning regimens were used with fludarabine or antithymocyte globulins. Eighty-nine patients underwent transplantation, 60 from peripheral-blood progenitor cells. Eighty-six patients received graft-versus-host disease (GHVD) prophylaxis for a median duration of 53 days.Seventy-nine patients engrafted, with 40 complete and 21 mixed chimerisms. The acute GHVD rate at 3 months was 50% +/- 11%. Fifty-two patients achieved complete remission and 12, partial remission. At 18 months after transplantation, the overall survival (OS) and the transplant-related mortality (TRM) were 32% +/- 12% and 38% +/- 14%, respectively. Initial diagnosis and disease status before transplantation significantly influenced survival. Age and GHVD prophylaxis type significantly influenced TRM. We also showed an impact of GHVD prophylaxis duration on OS and TRM. In multivariate analysis, three factors remained of prognostic value on OS: initial diagnosis, disease status at transplantation, and GHVD prophylaxis duration.This series shows encouraging results from nonmyeloablative conditioning regimens before allotransplantation and demonstrates the impact of some pre- and posttransplantation factors on outcome after transplantation.
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
Authors: Sergio Amadori, Stefan Suciu, Dominik Selleslag, Franco Aversa, Gianluca Gaidano, Maurizio Musso, Luciana Annino, Adriano Venditti, Maria Teresa Voso, Carla Mazzone, Domenico Magro, Paolo De Fabritiis, Petra Muus, Giuliana Alimena, Marco Mancini, Anne Hagemeijer, Francesca Paoloni, Marco Vignetti, Paola Fazi, Liv Meert, Safaa Mahmoud Ramadan, Roel Willemze, Theo de Witte, Frédéric Baron
Journal: Journal of Clinical Oncology (2016)

To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care (BSC) including hydroxyurea as first-line therapy in older patients with acute myeloid leukemia unsuitable for intensive chemotherapy.In this trial, patients at least 61 years old were centrally randomized (1:1) to receive either a single induction course of GO (6 mg/m(2) on day 1 and 3 mg/m(2) on day 8) or BSC. Patients who did not progress after GO induction could receive up to eight monthly infusions of the immunoconjugate at 2 mg/m(2). Randomization was stratified by age, WHO performance score, CD33 expression status, and center. The primary end point was overall survival (OS) by intention-to-treat analysis.A total of 237 patients were randomly assigned (118 to GO and 119 to BSC). The median OS was 4.9 months (95% CI, 4.2 to 6.8 months) in the GO group and 3.6 months (95% CI, 2.6 to 4.2 months) in the BSC group (hazard ratio, 0.69; 95% CI, 0.53 to 0.90; P = .005); the 1-year OS rate was 24.3% with GO and 9.7% with BSC. The OS benefit with GO was consistent across most subgroups, and was especially apparent in patients with high CD33 expression status, in those with favorable/intermediate cytogenetic risk profile, and in women. Overall, complete remission (CR [complete remission] + CRi [CR with incomplete recovery of peripheral blood counts]) occurred in 30 of 111 (27%) GO recipients. The rates of serious adverse events (AEs) were similar in the two groups, and no excess mortality from AEs was observed with GO.First-line monotherapy with low-dose GO, as compared with BSC, significantly improved OS in older patients with acute myeloid leukemia who were ineligible for intensive chemotherapy. No unexpected AEs were identified and toxicity was manageable.
Mammary Abscess
Authors: C. P. Mills
Journal: BMJ (1953)

MEDBRTSHRNAL 1427 the C, Pm2, and M2 teeth in the upper jaw; and the I1 tooth followed by the M1 tooth, and the C, Pm,., M2, and Pm2 teeth in that order in the lower jaw.The analysis indicates that the times of eruption of teeth with similar mean eruption times on the same side are independent of each other, but that the eruption times of corresponding teeth on the right and left sides are correlated.
Abstract 18761: Mechanical CPR associated With Decreased Survival From Out-of-hospital Cardiac Arrest
Authors: David Buckler, Kam Ching Li, Elizabeth Heisler, Douglas Kupas, Marion Leary, Benjamin Abella, Lance Becker
Journal: Circulation (2015)

Background: Randomized trials have shown mechanical CPR yields equivalent outcomes when compared to manual CPR for out-of-hospital cardiac arrest (OHCA). Many Emergency Medical Services (EMS) agencies have adopted mechanical CPR but data are lacking on the association of mechanical CPR with survival in real-world clinical practice. Objective: To assess the utilization of mechanical CPR and its association with survival to hospital discharge among adult cardiac arrest patients in Pennsylvania. Methods: Utilizing data from Pennsylvania within the Cardiac Arrest Registry to Enhance Survival, we identified all resuscitation events in which mechanical CPR was used and compared these to all other manual CPR cases. Events where ROSC occurred before mechanical CPR would have arrived on scene were excluded. Demographic and survival data were analyzed using chi-squared testing for categorical variables and t-test for continuous variables. Multivariable regression was used to control for confounding, including: age, witnessed arrest, arrest location, bystander CPR, arrest rhythm, and no flow time. Results: From 1/2012 to 12/2014, 10,457 cardiac arrests met inclusion criteria. Of those 1955 (19%) received mechanical CPR. Mean age was 66.7 ±15.9 years, and 34% received bystander CPR. Survival to hospital discharge was lower in the cohort receiving mechanical CPR compared to the cohort receiving manual CPR (106/1836 [5.8%] vs. 583/8048[7.2%], p=0.02). Good neurologic outcome was similarly reduced (80/1836[4.4%] vs. 453/8046[5.6%], p=0.02). In the adjusted model, use of mechanical CPR corresponded to reduced odds of survival to discharge (OR 0.75; CI 0.59-0.95; p=0.02) and good neurologic recovery (OR 0.75; CI 0.57-0.98; p=0.04). In this population, race or ethnicity were not associated with survival. We were unable to control for hospital and EMS agency characteristics or duration of resuscitation as possible confounders. Conclusions: Mechanical CPR is associated with a 25% lower likelihood of survival from OHCA in Pennsylvania, even after adjustments for patient and arrest characteristics. Further research needs to be conducted to understand factors associated with mechanical CPR use and OHCA outcomes, including possible unmeasured confounders.
Political diversity versus stimuli diversity: Alternative ways to improve social psychological science
Authors: Thomas Kessler, Jutta Proch, Stefanie Hechler, Larissa A Nägler
Journal: Behavioral and Brain Sciences (2015)

Abstract Instead of enhancing diversity in research groups, we suggest that in order to reduce biases in social psychological research a more basic formulation and systematic testing of theories is required. Following the important but often neglected ecological research approach would lead to systematic variation of stimuli and sometimes representative sampling of stimuli for specific environments.
Differences in Death Rates due to Injury Among Blacks and Whites, 1984
Authors: J A Gulaid, E C Onwuachi-Saunders, J J Sacks, D R Roberts
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of Chlorambucil on Thymidine Utilization by Yoshida Ascites Tumor Cells 2
Authors: Bridget T. Hill, Martin H. N. Tattersall
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Effect of Chlorambucil on Thymidine Utilization by Yoshida Ascites Tumor Cells Get access Bridget T. Hill, Bridget T. Hill Chester Beatty Research Institute, Institute of Cancer Research, Fulham Road, London SW3 6JB U.K. Search for other works by this author on: Oxford Academic PubMed Google Scholar Martin H. N. Tattersall Martin H. N. Tattersall Chester Beatty Research Institute, Institute of Cancer Research, Fulham Road, London SW3 6JB U.K. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 51, Issue 4, October 1973, Pages 1387–1390, https://doi.org/10.1093/jnci/51.4.1387 Published: 01 October 1973 Article history Received: 26 June 1973 Accepted: 17 July 1973 Published: 01 October 1973
Elevation of serum phosphate affects parathyroid hormone levels in only 50% of hemodialysis patients, which is unrelated to changes in serum calcium.
Authors: A Fine, D Cox, B Fontaine
Journal: Journal of the American Society of Nephrology (1993)

Hyperphosphatemia is said to cause hyperparathyroidism either by depressing the plasma levels of ionized calcium and/or by affecting serum 1,25(OH)2 vitamin D3 levels. Direct evidence that hyperphosphatemia contributes to hyperparathyroidism in hemodialysis patients is unclear because previous published data are with older parathyroid hormone (PTH) assays. Phosphate was added to the dialysate of 15 patients for 12 wk whose predialysis serum phosphates were between 1.5 and 1.9 mM (4.7 to 5.9 mg/dL) in order to further increase their serum phosphate by 0.75 mM (2.4 mg/dL) without adjustments in other medications. No patient was on vitamin D therapy. In half of the patients, PTH levels remained unchanged (nonresponders; 214 +/- 64 versus 219 +/- 60 ng/L), whereas in the other patients, PTH rose from 204 +/- 53 to 338 +/- 60 ng/L (P < 0.05; responders). The degree of induced hyperphosphatemia was virtually identical in both groups, 1.7 mM increasing to 2.4 mM. Ionized calcium was unchanged in both groups after phosphate. Plasma 1,25(OH)2 vitamin D3 levels were low to start with and remained low throughout. Nonresponders had been on dialysis twice as long as responders and had consumed over seven times more aluminum salts. Nonresponders had higher postdeferoxamine increments in plasma aluminum (3,588 +/- 1,466 versus 603 +/- 390; P < 0.05), although neither these amounts nor plasma levels were in the toxic range.(ABSTRACT TRUNCATED AT 250 WORDS)
Responses of Tumors Induced in Inbred Guinea Pig Strain JY-1 and Strain Hartley/F to BCG 2
Authors: Tetsuro Kataoka, Tohru Tokunaga, Toyoho Murohashi
Journal: JNCI Journal of the National Cancer Institute (1977)

A transplantable fibrosarcoma induced in inbred JY-1 guinea pig strain by 3-methylcholanthrene (MCA) and designated J4, an allotransplantable subline of J4 (JH4) which was obtained by the transplantation of J4 into the inbred Hartley/F guinea pig strain and maintained by passages in this strain, and a syngeneic liposarcoma H10 induced in a Hartley/F guinea pig by MCA were tested for their immunotherapeutic response with BCG. The growth of J4 and H10 tumors was suppressed in most of the animals when tumor cells were mixed with BCG before being injected sc into BCG-immune or BCG-nonimmune recipients. The growth of the JH4 tumor was suppressed at the sites of injection with a mixture of tumor cells and BCG in BCG-immune recipients but not in nonimmune animals. All guinea pigs surviving the injection of a tumor cell-BCG mixture resisted a second tumor cell challenge. When subcutaneous sarcomas grew to about 8-15 mm in diameter, BCG was injected into the tumors. The growth of JH4 tumor was not influenced by the injection in either BCG-immune or BCG-nonimmune animals, while the regression of the established J4 transplants was produced in 2 of 3 nonimmune recipients. The growth of the H10 tumor was not inhibited with an intratumor injection into nonimmune guinea pigs, while the H10 tumor regressed in BCG-immune animals for 4-5 weeks after intratumor injection and thereafter grew progressively. Skin reactions in animals that received repeated intradermal injections of the tumor cells and BCG were tested with 10(6) viable tumor cells as eliciting antigens. Typical delayed-type hypersensitivity reactions that were specific to the homologous antigens were observed. The possible reasons for the different responses to BCG among the guinea pig tumors, including line-10 hepatocarcinoma in strain-2 guinea pigs, were discussed.
First line tailored chemotherapy in advanced colorectal cancer (ACRC) with 5-fluouracil/leucovorin (5FU/LV) or oxaliplatin/irinotecan chosen by the expression of thymidylate synthase (TS) and dihydropyrimidine (DPD)
Authors: C. H. Smorenburg, G. J. Peters, C. J. Van Groeningen, P. Noordhuis, J. M. Van Riel, H. M. Pinedo, G. Giaccone
Journal: Journal of Clinical Oncology (2004)

3624 Background: Treatment of ACRC with 5FU/LV has a response rate (RR) < 25%. In a retrospective study both low TS and low DPD gene expression levels in metastases of ACRC were positive predictive factors of a response to 5FU (Salonga et al: CCR 2000). In contrast, the efficacy of oxaliplatin and irinotecan is supposedly independent of TS and DPD. Methods: Gene expression levels of TS and DPD using a quantitative RT-PCR assay were determined in pretreatment needle biopsies of metastatic tissue in previously untreated pts with ACRC. The cut-off values for TS and DPD relative to B-actin were 5 x 10 –3 and 45 x 10 -3, respectively. Chemotherapy consisted in arm A (low TS and low DPD) of weekly bolus 5FU/LV 500mg/m2 and in arm B (high TS and/or DPD) of 3-weekly oxaliplatin 85 mg/m2 and irinotecan 200 mg/m2. After progression, cross-over to the other regimen was allowed. Toxicity and response were evaluated every 3 and 9 weeks, respectively. Statistics using X2 test (one-sided, p<.05, 80 % power) required 20 evaluable pts in arm A to detect a significant increase of RR > 50%. Results: 47 out of 54 pts with a biopsy were treated in arm A (n=26) or arm B (n=21). 7 pts were not allocated to arm A or B due to deteriorating condition (3), other chemotherapy (2) and metastectomy (2). All pts in arm A were evaluable for response, and partial response (PR) was observed in 11 (RR 42 %) and stable disease (SD) in 9 pts. All but 1 pt in arm B were evaluable, with a PR in 5 (RR 25%) and SD in 9 pts. No responses were observed in 11 pts with a high TS/DPD after crossover to 5FU/LV, while crossover to the other regimen (n=10) resulted in 1 PR and 4 SD. No neutropenic fever or toxic deaths occurred. Conclusions: This study shows a higher efficacy of monotherapy with 5FU/LV in pts with a low level of TS and DPD than expected in unselected pts. As the need for fresh metastatic tumor tissue hampers this approach, investigation of alternative methods for TS and DPD assessment and other predictive markers is warranted. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis
CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma
Authors: Elisa M Noll, Christian Eisen, Albrecht Stenzinger, Elisa Espinet, Alexander Muckenhuber, Corinna Klein, Vanessa Vogel, Bernd Klaus, Wiebke Nadler, Christoph Rösli, Christian Lutz, Michael Kulke, Jan Engelhardt, Franziska M Zickgraf, Octavio Espinosa, Matthias Schlesner, Xiaoqi Jiang, Annette Kopp-Schneider, Peter Neuhaus, Marcus Bahra, Bruno V Sinn, Roland Eils, Nathalia A Giese, Thilo Hackert, Oliver Strobel, Jens Werner, Markus W Büchler, Wilko Weichert, Andreas Trumpp, Martin R Sprick
Journal: Nature Medicine (2016)
Hepatic arterial floxuridine infusion and patient survival.
Authors: C G Moertel
Journal: Journal of Clinical Oncology (1992)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1992.10.12.1986 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 1453215 Hepatic arterial floxuridine infusion and patient survival. C G MoertelxC G MoertelSearch for articles by this author https://doi.org/10.1200/JCO.1992.10.12.1986 First Page PDF © 1992 by American Society of Clinical Oncology